Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Perampanel 12 mg Tablets vs Fycompa in Healthy Volunteers
NCT06450223Phase 1Completed
- Sponsor
- Humanis
- Start
- Sep 2023
- Primary completion
- Sep 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perampanel in epilepsy (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 23 hours and AUC from time 0 to last collection time 72 at 23 hours. Started Sep 2023; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06450223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450223.